AIM: To evaluate the safety of adding ketoprofen to pegylated-interferon (PEG-IFN) with or without ribavirin and the effect on viral kinetics, STAT1 activity and expression of 2'-5'-oligoadenylate synthetase (2'-5'OAS) in genotype 1 chronic hepatitis C in a phase II study. METHODS:Forty-five patients were studied: fifteen were randomized toPEG-IFN plus ribavirin (PR), 16 to PEG-IFN plus ketoprofen and 14 to PR and ketoprofen. The molecular study of IFN-dependent signal transduction was conducted in 9 patients from each group. RESULTS: The combination of ketoprofen and PEG-IFN with or without ribavirin was safe and well tolerated. An early activation of STAT1 was observed in ketoprofen-treated patients, but this activation was less sustained over time. Conversely, ketoprofen plus PEG-IFN and ribavirin induced an early and sustained increase of 2'-5'OAS transcription starting 24 h after the first dose until the 36th wk. These data are consistent with the clinical results, showing a better sustained virological response and a lower relapse rate in patients receiving ketoprofen plus PEG-IFN and ribavirin. CONCLUSION: The addition of ketoprofen to the standard therapy of chronic hepatitis C should be explored in larger randomized clinical studies.
RCT Entities:
AIM: To evaluate the safety of adding ketoprofen to pegylated-interferon (PEG-IFN) with or without ribavirin and the effect on viral kinetics, STAT1 activity and expression of 2'-5'-oligoadenylate synthetase (2'-5'OAS) in genotype 1 chronic hepatitis C in a phase II study. METHODS: Forty-five patients were studied: fifteen were randomized to PEG-IFN plus ribavirin (PR), 16 to PEG-IFN plus ketoprofen and 14 to PR and ketoprofen. The molecular study of IFN-dependent signal transduction was conducted in 9 patients from each group. RESULTS: The combination of ketoprofen and PEG-IFN with or without ribavirin was safe and well tolerated. An early activation of STAT1 was observed in ketoprofen-treated patients, but this activation was less sustained over time. Conversely, ketoprofen plus PEG-IFN and ribavirin induced an early and sustained increase of 2'-5'OAS transcription starting 24 h after the first dose until the 36th wk. These data are consistent with the clinical results, showing a better sustained virological response and a lower relapse rate in patients receiving ketoprofen plus PEG-IFN and ribavirin. CONCLUSION: The addition of ketoprofen to the standard therapy of chronic hepatitis C should be explored in larger randomized clinical studies.
Authors: P Fabris; G Tositti; F Negro; F Marranconi; D Infantolino; M Rassu; F De Lalla Journal: Aliment Pharmacol Ther Date: 1999-10 Impact factor: 8.171
Authors: P Andreone; C Cursaro; A Gramenzi; S Fiorino; L Di Giammarino; R Miniero; A D'Errico; W F Grigioni; G Gasbarrini; M Bernardi Journal: Ital J Gastroenterol Hepatol Date: 1999-11
Authors: A E Muñoz; D Levi; A Podestá; J M Gorín; J González; M A Bartellini; M S Munne; A Cabanne; D Flichman; R Terg Journal: Gut Date: 2000-03 Impact factor: 23.059
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: G L Davis; R Esteban-Mur; V Rustgi; J Hoefs; S C Gordon; C Trepo; M L Shiffman; S Zeuzem; A Craxi; M H Ling; J Albrecht Journal: N Engl J Med Date: 1998-11-19 Impact factor: 91.245
Authors: Karina Trujillo-Murillo; Ana Rosa Rincón-Sánchez; Herminia Martínez-Rodríguez; Francisco Bosques-Padilla; Javier Ramos-Jiménez; Hugo A Barrera-Saldaña; Marcos Rojkind; Ana María Rivas-Estilla Journal: Hepatology Date: 2008-05 Impact factor: 17.425